Results 211 to 220 of about 95,190 (307)

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Muscle Infiltration in Chronic Lymphocytic Leukemia: A Diagnostic Challenge. [PDF]

Diagnostics (Basel)
Ichikawa J, Kirito K, Kawasaki T, Onohara K, Wako M, Haro H.   +5 more
europepmc   +1 more source

Comparative Analysis of Isavuconazole DDIs With Other Azole Antifungal Drugs and PBPK Model‐Informed Dosing Recommendations for Anticancer Drugs

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Isavuconazole is a broad‐spectrum triazole approved for the treatment of invasive aspergillosis or mucormycosis in adults and children aged ≥ 1 year. Current prescribing information lacks guidance regarding the co‐administration of isavuconazole with anticancer drugs–limited by the availability of clinical drug–drug interaction (DDI) data in ...
Theunis C. Goosen, Xiaofeng Wu, Jian Lin, Narayan Cheruvu, Susan R. Raber, Maria Lavinea Novis de Figueiredo, Manthena V. S. Varma   +6 more
wiley   +1 more source

Editorial: Reviews in hematologic malignancies: 2023

Frontiers in Oncology
Billy Michael Chelliah Jebaraj, Michael Liew, Felix Seyfried   +2 more
doaj   +1 more source

Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia Presenting as a Nasopharyngeal Mass With Bilateral Otitis Media With Effusion: A Case Report. [PDF]

Cureus
Aldawas G, Bhat IN, Alhamad S.
europepmc   +1 more source

Impaired expression of cell surface receptors for B cell growth factor by chronic lymphocytic leukemia B cells

, 1986
RT Perri
openalex   +1 more source

Optimizing Ibrutinib Posology in Chronic Lymphocytic Leukemia Using a Semi‐Mechanistic Pharmacometric Framework

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Ibrutinib, a Bruton's tyrosine kinase (Btk) inhibitor, is a key therapy for chronic lymphocytic leukemia (CLL). In clinical practice, adverse events, such as hypertension, frequently necessitate dose reductions or treatment discontinuation. Emerging evidence suggests that reduced doses may retain clinical efficacy while mitigating toxicity ...
Eman I. K. Ibrahim, Lena E. Friberg
wiley   +1 more source

Chronic Lymphocytic Leukemia: Novel Therapeutic Targets Under Investigation. [PDF]

Cancers (Basel)
Nayyar M, Menezes RCB, Ailawadhi S, Parrondo RD.   +3 more
europepmc   +1 more source

Application of Physiologically‐Based Pharmacokinetic Modeling to Support Drug Labeling: Prediction of CYP3A4‐Mediated Pirtobrutinib‐Drug Interactions

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Pirtobrutinib is a reversible Bruton tyrosine kinase (BTK) inhibitor. In vitro, pirtobrutinib is metabolized by cytochrome P450 (CYP) 3A4 and uridine 5′‐diphosphoglucuronosyl transferases (UGTs) and causes reversible and time‐dependent inhibition and induction of CYP3A4.
Dan‐Dan Tian, Stephen D. Hall, Sonya C. Chapman, Maria M. Posada   +3 more
wiley   +1 more source

Molecular Features Accompanying Richter's Transformation in Patients with Chronic Lymphocytic Leukemia. [PDF]

Int J Mol Sci
Wang X, Chen J.
europepmc   +1 more source